BACKGROUND AND OBJECTIVES: An increased incidence of renal cell carcinoma (RCC) in obese patients has been reported by several authors. We investigated the association of body mass index (BMI) with prognosis of patients with RCC. METHODS: From January 1994 to December 2000, 693 operations for RCC in 683 consecutive patients were performed at our institution. Patients' BMI at operation was evaluated, overall, tumor-specific and progression-free survival was investigated using the Kaplan-Meier method, for multivariate analysis the Cox regression model was used. RESULTS: Four hundred seventeen patients were males, 266 females. Mean age was 62 years (range 16-88). BMI was available in 609 (89.2%). 371/609 (60.9%) of patients exhibited a BMI greater than 25. After a mean follow-up of 41.5 months, 86 (12.6%) patients died from metastatic RCC, and 29 (4.3%) were alive with metastatic disease. A significant advantage regarding overall (P = 0.015) and progression-free (0.017) but not tumor-specific survival (P = 0.057) was found for patients with a BMI of more than 25 compared to normal-weight patients. In multivariate analysis, BMI showed no significant association with tumor-specific survival. CONCLUSIONS: Patients with a BMI of more than 25 had a better outcome compared to patients with normal weight in univariate analysis but not multivariate analysis. (c) 2004 Wiley-Liss, Inc.
BACKGROUND AND OBJECTIVES: An increased incidence of renal cell carcinoma (RCC) in obesepatients has been reported by several authors. We investigated the association of body mass index (BMI) with prognosis of patients with RCC. METHODS: From January 1994 to December 2000, 693 operations for RCC in 683 consecutive patients were performed at our institution. Patients' BMI at operation was evaluated, overall, tumor-specific and progression-free survival was investigated using the Kaplan-Meier method, for multivariate analysis the Cox regression model was used. RESULTS: Four hundred seventeen patients were males, 266 females. Mean age was 62 years (range 16-88). BMI was available in 609 (89.2%). 371/609 (60.9%) of patients exhibited a BMI greater than 25. After a mean follow-up of 41.5 months, 86 (12.6%) patients died from metastatic RCC, and 29 (4.3%) were alive with metastatic disease. A significant advantage regarding overall (P = 0.015) and progression-free (0.017) but not tumor-specific survival (P = 0.057) was found for patients with a BMI of more than 25 compared to normal-weight patients. In multivariate analysis, BMI showed no significant association with tumor-specific survival. CONCLUSIONS:Patients with a BMI of more than 25 had a better outcome compared to patients with normal weight in univariate analysis but not multivariate analysis. (c) 2004 Wiley-Liss, Inc.
Authors: S Waalkes; H Eggers; J Rustemeier; G Wegener; F Jentzmik; M Schrader; R Hofmann; M A Kuczyk; A J Schrader Journal: Urologe A Date: 2011-09 Impact factor: 0.639
Authors: Andres Jan Schrader; Julia Rustemeier; Jan Christoph Rustemeier; Nina Timmesfeld; Zoltan Varga; Axel Hegele; Peter Jochen Olbert; Rainer Hofmann Journal: J Cancer Res Clin Oncol Date: 2009-06-20 Impact factor: 4.553
Authors: Bumsoo Park; Byong Chang Jeong; Seong Il Seo; Seong Soo Jeon; Han Yong Choi; Hyun Moo Lee Journal: J Korean Med Sci Date: 2013-01-29 Impact factor: 2.153